Pyzina (Tablets) Instructions for Use
Marketing Authorization Holder
Lupin, Ltd. (India)
ATC Code
J04AK01 (Pyrazinamide)
Active Substance
Pyrazinamide (Rec.INN registered by WHO)
Dosage Form
| Pyzina | Tablets 500 mg: 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets are white, round, flat, with beveled edges, with the inscription “PYZINA LUPIN” and a break line on one side.
| 1 tab. | |
| Pyrazinamide | 500 mg |
Excipients: calcium phosphate dibasic dihydrate, pregelatinized starch, corn starch, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate, purified talc.
10 pcs. – blisters (10) – cartons.
100 pcs. – polyethylene bags (1) – plastic containers.
Clinical-Pharmacological Group
Antituberculosis drug
Pharmacotherapeutic Group
Antitubercular agent
Pharmacological Action
Synthetic second-line antituberculosis drug. The mechanism of action is not precisely known. It has a bacteriostatic or bactericidal effect depending on its concentration and the sensitivity of the microorganism. Penetrates well into foci of tuberculous lesions.
Pharmacokinetics
After oral administration, Pyrazinamide is rapidly absorbed from the gastrointestinal tract. Cmax in plasma is reached within 2 hours and is about 35 µg/ml at a dose of 1.5 g and 66 µg/ml at a dose of 2 g. Pyrazinamide is widely distributed in body tissues and fluids, penetrates the blood-brain barrier.
It is metabolized mainly in the liver by hydrolysis to form pyrazinoic acid, the main metabolite, which is gradually hydroxylated to 5-hydroxypyrazinoic acid.
T1/2 from plasma is about 9-10 hours.
It is excreted mainly by the kidneys via glomerular filtration. About 70% is found in the urine within 24 hours, mainly in the form of metabolites, and 4-14% as unchanged substance.
Indications
Tuberculosis (as part of combination therapy).
ICD codes
| ICD-10 code | Indication |
| A15 | Respiratory tuberculosis, bacteriologically and histologically confirmed |
| A17 | Tuberculosis of nervous system |
| A18 | Tuberculosis of other organs |
| ICD-11 code | Indication |
| 1B10.0 | Respiratory tuberculosis, bacteriologically or histologically confirmed |
| 1B11.Z | Tuberculosis of nervous system, unspecified |
| 1B12 | Tuberculosis of other systems and organs |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally.
Calculate the dose based on body weight.
For daily administration, use 15-25 mg/kg once per day.
For intermittent therapy, use 50-70 mg/kg two or three times per week.
Do not exceed the maximum daily dose of 2 grams.
Do not exceed the maximum intermittent dose of 3 grams when administered three times weekly or 4 grams when administered twice weekly.
Use only as part of a combination antituberculosis regimen to prevent the development of resistance.
Monitor liver transaminases and serum uric acid levels monthly during prolonged therapy.
Adverse Reactions
From the digestive system: impaired liver function, nausea, vomiting, diarrhea.
Allergic reactions: skin rash, itching, arthralgia.
Other: hyperuricemia, exacerbation of gout; rarely – photosensitivity.
Contraindications
Impaired liver function, hypersensitivity to pyrazinamide.
Use in Pregnancy and Lactation
Adequate and strictly controlled clinical studies on the safety of pyrazinamide use during pregnancy and lactation (breastfeeding) have not been conducted. However, if resistance to isoniazid, rifampicin, and ethambutol develops, the use of pyrazinamide in pregnant women may be considered.
Pyrazinamide is excreted in breast milk in small amounts.
Use in Hepatic Impairment
Contraindicated in impaired liver function.
Pediatric Use
Use is possible according to the dosing regimen.
Special Precautions
With monotherapy, resistance of mycobacteria to pyrazinamide develops rapidly, therefore Pyrazinamide is usually used in combination with other antituberculosis drugs.
Pyrazinamide is removed from the body by dialysis.
With long-term use, it is advisable to regularly (once a month) monitor the activity of liver transaminases and the content of uric acid in the blood.
Drug Interactions
Pyrazinamide reduces plasma concentrations of cyclosporine.
Pyrazinamide increases plasma concentrations of uric acid and reduces the effectiveness of antigout agents (allopurinol, sulfinpyrazone) with simultaneous use.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer